ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Corporate Overview January 16th

<< Previous

Bullboard Posts

Next >>

Comment by FarmerBettyon Jan 19, 2023 10:34am

165 Views

Post# 35233050

RE:RE:RE:RE:RE:RE:RE:RE:Corporate Overview January 16th

If they did file in December which i believe they didn't,the 30 days should be over or close as it is highly unlikely they filed between Christmas and Newyears.

The AD,ALS and PD programs need to go to a Pharma partner for clinical preparation and trials.
Promis with 5 employees and a few consultants does not have the scientific, technical, regulatory resources etc, to andvance these programs. As we've seen with Eisai / Biogen the competition is severe and the vultures and scientific field will through anything and everything to downplay even partilal success. Promis is not even close to being in a position to handle this.

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs